BI 2536

Catalog No.S1109

BI 2536 Chemical Structure

Molecular Weight(MW): 521.66

BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. It shows 4- and 11-fold greater selectivity against Plk2 and Plk3. Phase 2.

Size Price Stock Quantity  
In DMSO USD 240 In stock
USD 120 In stock
USD 210 In stock
USD 670 In stock
USD 997 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 56 Publications

13 Customer Reviews

  • (C) HeLa cells were treated with inhibitors of Aurora B (hesperadin), Aurora A (Aurora A inhibitor I), CDK1 (roscovitine), or PLK1 (BI2536) for 2 hours before immunostaining for tubulin and phosphorylated RV[S/T]F (p-RV[S/T]F). Nuclei are indicated with DAPI. Control cells were not treated with any inhibitor. More than 50 cells were imaged for each condition in three independent experiments. Scale bar, 20 μm.

    Science, 2018, 11(530), doi: 10.1126/scisignal.aai8669. BI 2536 purchased from Selleck.

    Comparison between Genetic Ablation of Cdc20 and Current Mitotic Drugs (C) Transformed Cdc20(lox/lox); RERT(+/Cre) MEFs were subcutaneously injected into the two flanks of SCID mice, and tumors were scored every 2-3 days.These mice were injected i.p. (three injections per week) with 4-OHT or mitotic drugs (taxol, vincristine, and BI2536) when tumors reached about 200 mm3 of volume (day 11; arrow) (n = 8 mice per group). (D) Representative images of these fibrosarcomas 3 days after injection with 4-OHT (to generate Cdc20(D/D) cells), BI2536, or taxol. These mice were injected with 10 μM BrdU to score DNA replication. CA3, immunodetection of active caspase 3. Scale bars, 50 or 10 μM (insets).

    Cancer Cell 2010 18, 641–654. BI 2536 purchased from Selleck.

  • (a,b) RPE1 cells transfected with control or either of two B56-PP2A siRNA pools (1, 2) were incubated in MG132 (10µM, 15 min), followed by the addition of BI2536 (40 nM) or DMSO for 45 min. (a) The frequency of mitotic cells with few or absent cold-stable K-bres . (b) Maximum-intensity projection of tubulin (green) and an overlay with kinetochores (CREST, red) in B56-PP2A-siRNA (pool 2) cells treated with DMSO or BI2536 (40 nM). Insets are 3 enlargement of the optical sections spanning the outlined centromeres.

    Nat Cell Biol 2011 13, 1265-71. BI 2536 purchased from Selleck.

    (a) HeLa Tet-On cells were treated with the indicated siRNAs, arrested in mitosis using 500 nM nocodazole (Noc) and 10 μM MG132, and then treated with or without BI 2536. The endogenous Cdc20 was immunoprecipitated from these cells and blotted with the indicated antibodies. The mitotic index of each sample is indicated below each lane. The bottom graph shows the quantification of the Cdc20-pS92 signal normalized to the total Cdc20 signal (mean±range; n=2 independent experiments).

    Nat Commun, 2016, 7:10818. BI 2536 purchased from Selleck.

  • Treatment with BI 2536 induces cell-cycle arrest in NB TICs and aberrant accumulation of cyclin B1 and p21. C, expression of cyclin B1 and p21 was assessed in NB88R2 following 16 and 24-hour treatment with different doses of BI 2536 (10, 30, and 100 nmol/L). ERK1 (extracellular signal regulated kinase 1) was used as the loading control. D, inhibition of PLK1 was assessed by in vitro kinase assay following treatment of NB88R2 for 3 hours with BI 2536.

    Cancer Res 2011 71, 1385-1395. BI 2536 purchased from Selleck.

    Treatment with BI 2536 induces cell death via apoptosis. A,treatment with BI 2536 (10, 30, and 100 nmol/L) reduces viable cell numbers as assessed by trypan blue exclusion. B, representative Western blot demonstrating accumulation of cleaved PARP following treatment with 10 nmol/L BI 2536.

    Cancer Res 2011 71, 1385-1395. BI 2536 purchased from Selleck.

  • BI 2536 inhibits NB tumor growth in vivo. A and B, NOD/SCID mice bearing 50- to100-mm3 tumors were injected intravenously with either vehicle (0.1N HCl per saline) or 12.5 to 25 mg/kg BI 2536 for 2 consecutive days a week, for a total of 3 cycles.Two independent experiments were performed in each case with 5 animals per group. Representative tumor growth data are shown.

     

     

    Cancer Res 2011 71, 1385-1395. BI 2536 purchased from Selleck.

    animals with 50- to 100-mm3 tumors were randomized into 4 groups: group 1 injected intravenously with vehicle (0.1N HCl per saline), group 2 injected intravenously with 12.5 mg/kg of BI 2536 (2 consecutive days, 3 cycles), group 3 injected i.p. with 10 mg/kg of irinotecan (3 doses total, 3 days apart), and group 4 injected with BI 2536 and irinotecan. Both representative tumor growth data and a Kaplan-Meyer survival plot are shown.

    Cancer Res 2011 71, 1385-1395. BI 2536 purchased from Selleck.

  • Plk-1 knockdown and inhibition by BI 2536 and viability of human melanoma cell lines M14 and WM-115 as demonstrated by MTT assay. Experiments were performed in triplicate. One representative experiment is shown. *P<0.001, ANOVA test with Tukey’s post-test. ANOVA, analysis of variance; MTT, 3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Plk-1, polo-like kinase 1; siRNA, small-interfering RNA; WB, western blot.

    J Invest Dermatol 2011 131, 1886–1895. BI 2536 purchased from Selleck.

    Western blot analysis of the expression and phosphorylation of Plk1, and phosphorylation of Myt1 in the CSC-like cells after treatment with BI 2536 for 24 and 48 hours, respectively.

    Oncotarget, 2017, 8(23):37633-37645. BI 2536 purchased from Selleck.

  • Cells with decreased GRK5 expression are more sensitive to PLK1 inhibition.A , shown is cell death in control or GRK5-shRNA stably transfected cells after 72 h of treatment with 0-120 nM BI 2536 as determined by trypan blue exclusion (n = 6).B , shown is cell death in control or GRK5-shRNA stably transfected cells after 72 h treatment with 0 –120 nM GSK461364, as determined by trypan blue exclusion ( n = 4).

    J Biol Chem 2012 287(21), 17088-99. BI 2536 purchased from Selleck.

    J Biomol Screen 2013 18(1), 54-66. BI 2536 purchased from Selleck.

  • Example dose response curves of the PLK-1 inhibitor BI-2536. During the large dose response study for each reference compounds 8 dilutions were tested. Curves for IC50 determination for two independent experiments for the PLK1 inhibitor BI-2536 are displayed. This inhibitor is also used to achieve the LC values. IC50 has been determined with 7.48 +/- 0.09 log [M] and 6.75 +/- 0.21 log [M]. Correlating assay performance data are displayed in Suppl. Fig. 5. 

    J Biomol Screen 2013 18(1), 54-66. BI 2536 purchased from Selleck.

Purity & Quality Control

Choose Selective PLK Inhibitors

Biological Activity

Description BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. It shows 4- and 11-fold greater selectivity against Plk2 and Plk3. Phase 2.
Features The first potent and selective Plk1 inhibitor that induces all hallmarks of Plk1 inhibition.
Targets
PLK1 [1]
(Cell-free assay)
PLK2 [1]
(Cell-free assay)
PLK3 [1]
(Cell-free assay)
0.83 nM 3.5 nM 9.0 nM
In vitro

BI 2536 blocks the activities of Plk2 and Plk3 to a slightly lesser extent with IC50 of 3.5 nM and 9.0 nM, respectively. In HeLa cells, BI 2536 treatment ranging from 10-100 nM leads to the blocking of the recruitment of γ-tubulin and phosphorylation of Apc6 at mitotic centrosomes, inhibition of cohesin release from chromosome arms, induction of monopolar spindles, as well as a range of other mitotic processes that are known to depend on Plk1. BI 2536 treatment leads to the HeLa cells arrested in G2/M, subsequently a sub-G1 DNA peak indicative of DNA breakdown and apoptosis, and accumulated cleaved PARP p85 fragments in a concentration-dependent manner. BI 2536 inhibits the growth of a panel of 32 human cancer cell lines with EC50 of 2-25 nM, while blocking the proliferation of exponentially growing hTERT-RPE1, human umbilical vein endothelial cells (HUVECs), and normal rat kidney (NRK) cells with EC50 of 12-31 nM. [1] Plk1 inhibition by BI 2536 reduces the growth and viability of anaplastic thyroid carcinoma (ATC) cells such as CAL62, OCUT-1, SW1736, 8505C, and ACT-1 with EC50 values of 1.4-5.6 nM. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PSN1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XmWmlEPTB;MD6wNFc4PiEQvF2= M4Dnb3NCVkeHUh?=
ACN M2\4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV24V3V3UUN3ME2wMlAxQDR|IN88US=> M3vWRnNCVkeHUh?=
TE-8 NH\wPFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTBwMEC5OFEh|ryP MmLHV2FPT0WU
LC-2-ad NUf3VlVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fIWWlEPTB;MD6wNVA6OyEQvF2= NGPrfoNUSU6JRWK=
ALL-PO M1O3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTBwMEGzJO69VQ>? MmTUV2FPT0WU
EW-16 Mn33S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTBwMEGzN|Yh|ryP MULTRW5ITVJ?
KM12 MkPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlH4TWM2OD1yLkCxN|Q5KM7:TR?= NUn0OHc{W0GQR1XS
GI-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zJWWlEPTB;MD6wNVM5OyEQvF2= M2X5T3NCVkeHUh?=
LS-411N MnzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDCdJJKSzVyPUCuNFE1ODdizszN NXrBOVR6W0GQR1XS
ES8 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HKV2lEPTB;MD6wNVQ6PCEQvF2= Mo[2V2FPT0WU
SNU-C2B NIjjSXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHWzXItKSzVyPUCuNFE2OjZizszN MmXLV2FPT0WU
CESS Ml;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2facGlEPTB;MD6wNVYxOiEQvF2= NEPKdFhUSU6JRWK=
697 M4LnSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvSdIVNUUN3ME2wMlAyPjZ6IN88US=> MULTRW5ITVJ?
NCI-H1963 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknSTWM2OD1yLkCxOlc{KM7:TR?= NU[0V3Y4W0GQR1XS
IA-LM MlXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXy[ZVKSzVyPUCuNFE3QDhizszN NHfhNYpUSU6JRWK=
SW954 NFrWeWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTBwMEG3NFUh|ryP MlXYV2FPT0WU
RL95-2 MnvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXuyc2tzUUN3ME2wMlAyPzN6IN88US=> M{m4O3NCVkeHUh?=
LXF-289 NWruOoo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjFco9HUUN3ME2wMlAyPzdizszN M{jMVXNCVkeHUh?=
OCUB-M NGflZ2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTBwMEG4NlYh|ryP NEHLNohUSU6JRWK=
RKO Mnj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\nVGlEPTB;MD6wNVk5PyEQvF2= MWrTRW5ITVJ?
LOUCY Mon4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwMEKwOUDPxE1? NEDWN2dUSU6JRWK=
NOS-1 M{TxeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTBwMEKwPVMh|ryP NF\vXXRUSU6JRWK=
A4-Fuk M2nvPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3mVlJKSzVyPUCuNFIzOThizszN NVi1b4t3W0GQR1XS
A388 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnWdXpDUUN3ME2wMlAzOjJ5IN88US=> MonwV2FPT0WU
TE-9 M1TvTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULidodzUUN3ME2wMlAzOjZzIN88US=> Mkn1V2FPT0WU
KURAMOCHI MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoG1TWM2OD1yLkCyNlg2KM7:TR?= NH7MVpNUSU6JRWK=
KALS-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fQbGlEPTB;MD6wNlM{QCEQvF2= NWrhNZZzW0GQR1XS
HOP-62 M4nUdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoK4TWM2OD1yLkCyOFIh|ryP NVPXO2hwW0GQR1XS
RPMI-8402 M{joPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWO2e3F6UUN3ME2wMlAzPTB6IN88US=> M4[1bXNCVkeHUh?=
TE-1 NFLUTnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTBwMEK1NVIh|ryP NH\JR3pUSU6JRWK=
CCRF-CEM NUTHdlIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjOWJdKSzVyPUCuNFI2PDNizszN NHHnNFhUSU6JRWK=
HUTU-80 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3n5bGlEPTB;MD6wNlYzPCEQvF2= MYXTRW5ITVJ?
NCI-H1648 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwMEK2OFch|ryP NVnZdYVsW0GQR1XS
HCE-4 M1T5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTBwMEK2PFIh|ryP NYTSVIFJW0GQR1XS
ETK-1 M1;EZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mln6TWM2OD1yLkCyO|M3KM7:TR?= M3PpcXNCVkeHUh?=
TE-15 NX7vUJh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIj0[JdKSzVyPUCuNFI4OzhizszN MnX5V2FPT0WU
BE-13 M1;k[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEKzUoZKSzVyPUCuNFI4PCEQvF2= NWLjcpBHW0GQR1XS
KE-37 M1XWZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwMEK3OFEh|ryP NYnUe|dyW0GQR1XS
NCI-H1355 NYTtXYdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLXeZlYUUN3ME2wMlAzPzh|IN88US=> M3TFT3NCVkeHUh?=
TE-11 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzmZVlKSzVyPUCuNFI5ODlizszN NH\y[m9USU6JRWK=
BL-70 Mn3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;PUVhKSzVyPUCuNFI5PTdizszN NHnxdVVUSU6JRWK=
ES6 M1[ySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\kUVFKSzVyPUCuNFI5QDFizszN NH3YZ4RUSU6JRWK=
GT3TKB NHXSOXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2S0dWlEPTB;MD6wNlk2OyEQvF2= NGiySmVUSU6JRWK=
LB647-SCLC MkHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnITGVSUUN3ME2wMlA{OTl3IN88US=> NWrZ[JFIW0GQR1XS
NB13 MnfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHT4WoRKSzVyPUCuNFM{OTZizszN M4jLSHNCVkeHUh?=
ST486 NF3nPGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwMEOzN|ch|ryP M1nrc3NCVkeHUh?=
NCI-H82 NETxSWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3zZ|ZxUUN3ME2wMlA{OzR|IN88US=> MnHBV2FPT0WU
NTERA-S-cl-D1 NWLmNlByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPofolEUUN3ME2wMlA{Ozl7IN88US=> MUHTRW5ITVJ?
ES4 NVGxbINJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XyUGlEPTB;MD6wN|Q3OyEQvF2= NF3NfFFUSU6JRWK=
SK-NEP-1 NG\5NWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHiW2hKSzVyPUCuNFM1QTlizszN Mn\kV2FPT0WU
Becker Mkf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmm3TWM2OD1yLkCzOVU2KM7:TR?= MXrTRW5ITVJ?
A101D NGTLTZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHmXZlRUUN3ME2wMlA{PzR6IN88US=> MUXTRW5ITVJ?
SK-UT-1 M4nMVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3rTWM2OD1yLkCzO|c1KM7:TR?= MYDTRW5ITVJ?
SW982 NFjWdnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPNSVNXUUN3ME2wMlA{PzlizszN NXXVTI5sW0GQR1XS
TE-10 NVXRO2N6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFj0OW1KSzVyPUCuNFQxPDZizszN NITJeZdUSU6JRWK=
OVCAR-4 MmrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\CWmlEPTB;MD6wOFA2QSEQvF2= NITRd5ZUSU6JRWK=
KP-N-YS NWS3c4hVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4[5VGlEPTB;MD6wOFA5PSEQvF2= MWfTRW5ITVJ?
BL-41 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTjTWM2OD1yLkC0NVI2KM7:TR?= MnrDV2FPT0WU
MZ1-PC NVPyZXRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlz3TWM2OD1yLkC0NVI4KM7:TR?= NHzOOWJUSU6JRWK=
PF-382 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jERmlEPTB;MD6wOFE6QCEQvF2= NUmzNYhLW0GQR1XS
MOLT-13 NWfCcJMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3f3fmlEPTB;MD6wOFI{QCEQvF2= MU\TRW5ITVJ?
HCC1599 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXWzO4xNUUN3ME2wMlA1OjV6IN88US=> M1iwXHNCVkeHUh?=
IST-MEL1 NI\jT|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXRTWM2OD1yLkC0OFQzKM7:TR?= Mk\IV2FPT0WU
LU-139 NYLBSpp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moi1TWM2OD1yLkC0OFQzKM7:TR?= MlnjV2FPT0WU
MS-1 MoniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fKXWlEPTB;MD6wOFcxOSEQvF2= MoDBV2FPT0WU
MFH-ino NEW5RnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;yW2lEPTB;MD6wOVAxOyEQvF2= MVnTRW5ITVJ?
IMR-5 MnL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\2TWM2OD1yLkC1NFIyKM7:TR?= NGCyOJJUSU6JRWK=
TE-5 M3rQSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHPTWM2OD1yLkC1NFY{KM7:TR?= MV3TRW5ITVJ?
DJM-1 M2G4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfTR4RKSzVyPUCuNFUyPDJizszN M16yPHNCVkeHUh?=
NB17 M3T6c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fJXWlEPTB;MD6wOVIxPyEQvF2= MlnQV2FPT0WU
KARPAS-45 M{TmWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3W5NWlEPTB;MD6wOVM2QCEQvF2= NFz5cpBUSU6JRWK=
TGBC1TKB NVWxOoo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTBwMEW0NFUh|ryP M1TTbXNCVkeHUh?=
ML-2 MnTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrkTWM2OD1yLkC1OFE1KM7:TR?= M2Tr[nNCVkeHUh?=
no-10 NHmxNVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrkTWM2OD1yLkC1OFc1KM7:TR?= MoXzV2FPT0WU
CTV-1 M17QXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2f2ZmlEPTB;MD6wOVUxOiEQvF2= MXnTRW5ITVJ?
SJSA-1 NIHrbmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnP1TWM2OD1yLkC1OVIh|ryP NVHHPFBnW0GQR1XS
HC-1 NWOxcW56T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX2zSmdbUUN3ME2wMlA2PTl5IN88US=> NFPoXJpUSU6JRWK=
TE-12 M3nxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTBwMEW2NVMh|ryP NEXueHFUSU6JRWK=
KY821 NWfYcW1[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7mTWM2OD1yLkC1OlMzKM7:TR?= MYfTRW5ITVJ?
TALL-1 M3rKd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTBwMEW3NFgh|ryP MkH4V2FPT0WU
DEL M1zrT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWL0WoJ4UUN3ME2wMlA2PzB7IN88US=> M1\FOnNCVkeHUh?=
TE-6 M1nWW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTBwMEW3NlIh|ryP Mle1V2FPT0WU
SK-LMS-1 MonwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPQSpJKSzVyPUCuNFU5ODVizszN Mm\NV2FPT0WU
EW-1 NFTlWldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPuTWM2OD1yLkC1PFM4KM7:TR?= MX\TRW5ITVJ?
8-MG-BA NECzUmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkD0TWM2OD1yLkC1PFUyKM7:TR?= M4TuWHNCVkeHUh?=
NALM-6 M4TmSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTGNpU2UUN3ME2wMlA2QTd|IN88US=> NFHnN2hUSU6JRWK=
LB771-HNC MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTBwMEW5O|kh|ryP MmfMV2FPT0WU
HT-144 M1Wydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTBwME[xN{DPxE1? MVPTRW5ITVJ?
KM-H2 MljLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLjOnl{UUN3ME2wMlA3OjJzIN88US=> NEe4NJVUSU6JRWK=
SF268 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjzfnpKSzVyPUCuNFYzQDZizszN NYjCN2RkW0GQR1XS
RS4-11 MoDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTBwME[zNFQh|ryP MWrTRW5ITVJ?
MHH-PREB-1 MnTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfFUnVKSzVyPUCuNFY{OTlizszN Ml23V2FPT0WU
ATN-1 M4CwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGX1dolKSzVyPUCuNFY{PDVizszN MW\TRW5ITVJ?
BB30-HNC MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvUTGpoUUN3ME2wMlA3PDN4IN88US=> MX3TRW5ITVJ?
CPC-N NELsTXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXVfFhIUUN3ME2wMlA3PTJ2IN88US=> MoraV2FPT0WU
NB1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTBwME[2NVMh|ryP M1LXPHNCVkeHUh?=
KS-1 Mn3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmm0TWM2OD1yLkC2O|Q5KM7:TR?= NGP4SHVUSU6JRWK=
RXF393 Mk\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYj5e5ZlUUN3ME2wMlA3PzZ2IN88US=> M{W3TnNCVkeHUh?=
IST-SL2 M{\2bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTBwMEewNFQh|ryP M1zaS3NCVkeHUh?=
GI-ME-N NH;RTGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPUTFhKSzVyPUCuNFczQDZizszN NFLicndUSU6JRWK=
VA-ES-BJ NGXNWlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPWTWM2OD1yLkC3OFc2KM7:TR?= MUTTRW5ITVJ?
NCI-H1581 NXLJUpluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TNT2lEPTB;MD6wO|Q4QCEQvF2= Mlm1V2FPT0WU
U-266 NYruWWxRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PmTGlEPTB;MD6wO|Q6PyEQvF2= NFXu[3NUSU6JRWK=
DMS-114 M4TLbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1m1WWlEPTB;MD6wO|UzQCEQvF2= MmjVV2FPT0WU
NCI-H187 M2LoNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnXTWM2OD1yLkC3O|I3KM7:TR?= MU\TRW5ITVJ?
SW962 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTBwMEe4N|kh|ryP M3S1bHNCVkeHUh?=
MONO-MAC-6 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTBwMEe5PFYh|ryP NX3DbYI3W0GQR1XS
MOLT-16 NYPCUlI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnHOllHUUN3ME2wMlA5OTJzIN88US=> MYrTRW5ITVJ?
KNS-42 M{fhUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XSemlEPTB;MD6wPFE3OSEQvF2= MoD4V2FPT0WU
CMK M{C1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWru[4J6UUN3ME2wMlA5OjJ3IN88US=> MUPTRW5ITVJ?
Ramos-2G6-4C10 M{XISmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLQTWM2OD1yLkC4NlI2KM7:TR?= NFnQUY5USU6JRWK=
Daudi MlfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTBwMEiyOVYh|ryP MoK4V2FPT0WU
NCI-H510A NXvvdIJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorFTWM2OD1yLkC4N|M3KM7:TR?= NF3VbYZUSU6JRWK=
LB831-BLC M2PuWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jPemlEPTB;MD6wPFU3OSEQvF2= MmnEV2FPT0WU
HEL NHzxcnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTBwMEi2Olgh|ryP MmT6V2FPT0WU
LU-134-A NHPyOYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nyOWlEPTB;MD6wPFcxQCEQvF2= MnvJV2FPT0WU
NCI-H1694 M{jTc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTBwMEi3OFQh|ryP MmW0V2FPT0WU
KGN NXK1TYpzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4O0bmlEPTB;MD6wPFc2QSEQvF2= NYfjXpMxW0GQR1XS
A253 MnjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwMEi4NlIh|ryP NInobXVUSU6JRWK=
DG-75 NV\icIdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLETWM2OD1yLkC4PVIzKM7:TR?= M{jrZXNCVkeHUh?=
MOLT-4 Mn:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwMEi5PFMh|ryP MmPpV2FPT0WU
NCI-SNU-5 M1LBZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HBOWlEPTB;MD6wPVI2QCEQvF2= NYTWO2toW0GQR1XS
ONS-76 NVrl[lN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moq4TWM2OD1yLkC5Nlc3KM7:TR?= M4rBNXNCVkeHUh?=
NCI-H446 MoP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTBwMEm0OlIh|ryP MWfTRW5ITVJ?
COR-L279 MlPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTBwMEm1OVYh|ryP NVr6XmJnW0GQR1XS
Calu-6 M2[3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnqzTWM2OD1yLkC5OVk5KM7:TR?= NUP6eIFiW0GQR1XS
BC-3 M{LESWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTBwMEm2OlIh|ryP MX;TRW5ITVJ?
NCI-H2126 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTBwMEm3PVEh|ryP M1zx[3NCVkeHUh?=
NCI-H1882 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlv3TWM2OD1yLkC5PFA6KM7:TR?= M2Kxd3NCVkeHUh?=
BB65-RCC NYnmRZlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3BTWM2OD1yLkGwNlk1KM7:TR?= MYXTRW5ITVJ?
DU-4475 NXPiXpd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTBwMUC0NFch|ryP MVPTRW5ITVJ?
NCI-H526 M{[5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TZUmlEPTB;MD6xNFQ1KM7:TR?= MojFV2FPT0WU
NEC8 NFnB[ZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmCyTWM2OD1yLkGwOVI2KM7:TR?= MXzTRW5ITVJ?
NCI-H1304 M4jlb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTSTlV2UUN3ME2wMlExPTl2IN88US=> NXHHeoJ[W0GQR1XS
L-540 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoX4TWM2OD1yLkGwO|A5KM7:TR?= NHfrZ3hUSU6JRWK=
NCI-SNU-16 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVy3ZpJDUUN3ME2wMlExPzR{IN88US=> NWTDXodDW0GQR1XS
HD-MY-Z Mn7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\wNWlEPTB;MD6xNFg2PiEQvF2= NVLOc3JLW0GQR1XS
K-562 Ml\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVryTnZPUUN3ME2wMlExQDV6IN88US=> MonMV2FPT0WU
JAR M4W5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4qyd2lEPTB;MD6xNFkzPSEQvF2= MkXaV2FPT0WU
MZ2-MEL Mm\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\1TWM2OD1yLkGxNFUh|ryP NFnu[VlUSU6JRWK=
L-363 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTBwMUGwO|kh|ryP Mn;IV2FPT0WU
BV-173 M4GxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfhNZlKSzVyPUCuNVEzPDNizszN NETGU2FUSU6JRWK=
NCI-H524 NU\xeoZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXJTWM2OD1yLkGxNlc1KM7:TR?= Ml;1V2FPT0WU
EoL-1-cell Moj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XRSmlEPTB;MD6xNVY4OiEQvF2= NEDacZJUSU6JRWK=
K052 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTBwMUG3NVIh|ryP MYrTRW5ITVJ?
TK10 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPtR2NKSzVyPUCuNVE4OjhizszN NHr4S3FUSU6JRWK=
KU812 M175e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3LNXFKSzVyPUCuNVIxPDRizszN NYfMZ3JpW0GQR1XS
RPMI-8226 M3vtWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M362c2lEPTB;MD6xNlA2OiEQvF2= MWfTRW5ITVJ?
MZ7-mel MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTBwMUKyN|ch|ryP M4fWTnNCVkeHUh?=
SK-PN-DW MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPOTWM2OD1yLkGyNlg4KM7:TR?= NVTPcWJQW0GQR1XS
SR NF[0THFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XwOGlEPTB;MD6xNlQ1OSEQvF2= M1rzTXNCVkeHUh?=
RPMI-6666 M322PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1X0NWlEPTB;MD6xNlc1OyEQvF2= MXjTRW5ITVJ?
no-11 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7mWGJKSzVyPUCuNVI5PjlizszN NXPmNpJGW0GQR1XS
EW-3 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fjd2lEPTB;MD6xNlg6OyEQvF2= NVjFfXRKW0GQR1XS
LAMA-84 NWC1OnFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnsTWM2OD1yLkGzNVg4KM7:TR?= MnThV2FPT0WU
HT MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LEXGlEPTB;MD6xN|U4PCEQvF2= NG[xPI9USU6JRWK=
KP-N-RT-BM-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3GTWM2OD1yLkGzOlEzKM7:TR?= NVfyfJRtW0GQR1XS
NCI-H747 NI\NU5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTBwMUO3JO69VQ>? MonwV2FPT0WU
NCCIT NYjaUVJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjjTWM2OD1yLkGzPVM6KM7:TR?= M3SwWHNCVkeHUh?=
MLMA NWnqVJNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkn5TWM2OD1yLkG0NVY4KM7:TR?= MkDOV2FPT0WU
LP-1 MnXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoL0TWM2OD1yLkG0NlQh|ryP M3u3THNCVkeHUh?=
CAL-148 M1HyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIOzTFJKSzVyPUCuNVQ1QDNizszN NV[0TVZCW0GQR1XS
GB-1 MlTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\ScGlEPTB;MD6xOFUzPiEQvF2= MmDZV2FPT0WU
COR-L88 NGXHfWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTBwMUS4NFIh|ryP M4LON3NCVkeHUh?=
NKM-1 NYn1VGRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTBwMUS5NFYh|ryP NXLjRZpzW0GQR1XS
NB5 NVfNeWVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLXZ|ZRUUN3ME2wMlE2PDZ{IN88US=> MYjTRW5ITVJ?
SH-4 NGLIZpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTBwMUW0OlYh|ryP M1HncXNCVkeHUh?=
EM-2 MnTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXX[GNUUUN3ME2wMlE2PDZ5IN88US=> MlLRV2FPT0WU
TGBC24TKB MmnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTXc21KSzVyPUCuNVU3PTlizszN M2Xm[nNCVkeHUh?=
SCLC-21H M3nIbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTBwMUW3NFIh|ryP NILyRolUSU6JRWK=
COLO-684 NEC2bFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwMUW3NlEh|ryP MXPTRW5ITVJ?
KINGS-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFe2V3hKSzVyPUCuNVU6OSEQvF2= MYXTRW5ITVJ?
LS-123 NFrhVZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHWTZBKSzVyPUCuNVU6OTdizszN NFvnVZZUSU6JRWK=
MC116 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfXTWM2OD1yLkG2NVU5KM7:TR?= NV[4bXFwW0GQR1XS
SU-DHL-1 M1LkR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTBwMU[yNFYh|ryP MnLGV2FPT0WU
NCI-H64 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfxTWM2OD1yLkG2N|Q4KM7:TR?= Ml;KV2FPT0WU
HCE-T MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYf3UnVTUUN3ME2wMlE3PTB2IN88US=> NWjSWFU5W0GQR1XS
LOXIMVI NUjrTIQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPTTWM2OD1yLkG2PVQ6KM7:TR?= NXTHe5lmW0GQR1XS
ARH-77 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3wbmpKSzVyPUCuNVc{PzlizszN MljWV2FPT0WU
DOHH-2 M{\qRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXtb4pCUUN3ME2wMlE4Pjd{IN88US=> NYjQbmhWW0GQR1XS
COLO-320-HSR MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4n5SWlEPTB;MD6xPFE2PCEQvF2= NWCySZlsW0GQR1XS
NB6 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYKweXBrUUN3ME2wMlE5PTZ4IN88US=> M3XOUHNCVkeHUh?=
L-428 NVvwN4duT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjscYFKSzVyPUCuNVg5OTNizszN NV2wW4xHW0GQR1XS
SNB75 NEC5ZpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPZVGdwUUN3ME2wMlE5QDJ2IN88US=> MWrTRW5ITVJ?
NCI-H2141 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTBwMUmwNVEh|ryP M1PxbnNCVkeHUh?=
KARPAS-299 NGS0cotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFu2OXhKSzVyPUCuNVkzPDFizszN NUTTNpYzW0GQR1XS
LC4-1 M3q3dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7vTWM2OD1yLkG5OVAzKM7:TR?= MmX5V2FPT0WU
UACC-257 NFznOWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwMUm5OFch|ryP M2XwcnNCVkeHUh?=
EVSA-T NWrGcmRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTBwMkCzNVIh|ryP MUTTRW5ITVJ?
JiyoyeP-2003 NHnrcFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrxU|Z5UUN3ME2wMlIxPDd5IN88US=> M1ziR3NCVkeHUh?=
NCI-H720 NEewZZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7aTHRVUUN3ME2wMlIxPTJ3IN88US=> MXzTRW5ITVJ?
GAK NGHk[GxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTBwMkGxPFkh|ryP MnfyV2FPT0WU
HH MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjsOmNKSzVyPUCuNlE1ODVizszN NFe3SHdUSU6JRWK=
NCI-H1436 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XqWWlEPTB;MD6yNVQ3PCEQvF2= MY\TRW5ITVJ?
GR-ST NHn4b4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLOOWt4UUN3ME2wMlIyPDh6IN88US=> MlXIV2FPT0WU
BC-1 NFrxdItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTBwMkK2NVYh|ryP M{\Zc3NCVkeHUh?=
SIG-M5 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XacGlEPTB;MD6yNlczPyEQvF2= M3;NXXNCVkeHUh?=
NCI-H345 MlrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTBwMkO4NFUh|ryP Ml:5V2FPT0WU
OPM-2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwMkO4PFIh|ryP M3jVN3NCVkeHUh?=
LB1047-RCC MlXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLxWo8xUUN3ME2wMlI1PDFizszN Mmi2V2FPT0WU
CTB-1 NFzCV2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rqZmlEPTB;MD6yOFQ6OyEQvF2= NX7Pe5pHW0GQR1XS
A3-KAW NILN[W1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3qZnNKSzVyPUCuNlU{PDFizszN MXLTRW5ITVJ?
SF126 M1vTRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLMTWM2OD1yLkK1N|g{KM7:TR?= NY\FWpVuW0GQR1XS
KARPAS-422 MkfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLCbJZzUUN3ME2wMlI2PDN3IN88US=> MUDTRW5ITVJ?
MEG-01 M{DIR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwMkW2O|Mh|ryP NHf1WoJUSU6JRWK=
NCI-H209 Ml\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXL6dFZMUUN3ME2wMlI3Ozd2IN88US=> M4XZVnNCVkeHUh?=
SBC-1 NX64PGpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrMeYt[UUN3ME2wMlI3PSEQvF2= M1vmNHNCVkeHUh?=
K5 NWWxbZd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPKTWM2OD1yLkK2PVg1KM7:TR?= NW\tN|dOW0GQR1XS
QIMR-WIL MorNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXzPJNyUUN3ME2wMlI4OTV3IN88US=> NYjNWmxSW0GQR1XS
NMC-G1 MojsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjiXoJRUUN3ME2wMlI5OjF5IN88US=> MlnVV2FPT0WU
IST-MES1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17IZWlEPTB;MD6yPVI{QCEQvF2= MknZV2FPT0WU
SW684 M3P1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTBwM{CwOFch|ryP M4nufHNCVkeHUh?=
MV-4-11 NXfP[WhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXXZ2ZKSzVyPUCuN|A4QDhizszN NV32Z5p6W0GQR1XS
LAN-6 NFfuOlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmKyTWM2OD1yLkOxOVczKM7:TR?= NH3uXWhUSU6JRWK=
RH-1 M2W2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fPd2lEPTB;MD6zNVg4OSEQvF2= M4DCdnNCVkeHUh?=
CP66-MEL MlnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LFV2lEPTB;MD6zNVg4QCEQvF2= M4DEc3NCVkeHUh?=
EC-GI-10 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwM{K5PFch|ryP MWnTRW5ITVJ?
GDM-1 MmH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljiTWM2OD1yLkOzNFU6KM7:TR?= MnXYV2FPT0WU
IST-SL1 M3TkV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfLeZZYUUN3ME2wMlM1QTF2IN88US=> NEDRfZFUSU6JRWK=
KMOE-2 NWrGWZZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4GyUGlEPTB;MD6zOVE4PSEQvF2= NHHXcnhUSU6JRWK=
OS-RC-2 NWfwXmN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\mUGlEPTB;MD6zOVU1PCEQvF2= NVnSNYdCW0GQR1XS
HDLM-2 M3ThfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXIcotGUUN3ME2wMlM4QDF2IN88US=> MYDTRW5ITVJ?
DSH1 NXyxe3dnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXzTGtKSzVyPUCuN|g3OzFizszN MnGyV2FPT0WU
LS-1034 NWX4W2xnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofNTWM2OD1yLkO4PVU1KM7:TR?= M1j4UXNCVkeHUh?=
LB373-MEL-D Moe4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfQco5KSzVyPUCuN|kyQTdizszN NHnDXYFUSU6JRWK=
GOTO NHrYO4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfofI1lUUN3ME2wMlQzOTF6IN88US=> NHHZOmdUSU6JRWK=
MRK-nu-1 NWDqVZNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTBwNEKyNFUh|ryP M1vqTHNCVkeHUh?=
SK-MM-2 M4DvNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE[1[2JKSzVyPUCuOFM1PDJizszN MWXTRW5ITVJ?
BOKU MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PHXWlEPTB;MD60N|c6OiEQvF2= NYjnW4E5W0GQR1XS
NOMO-1 NG\odlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHn0WnhKSzVyPUCuOFM5PiEQvF2= NWLBPGozW0GQR1XS
J-RT3-T3-5 MkLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVe5cG5uUUN3ME2wMlQ1QDd6IN88US=> MUfTRW5ITVJ?
COLO-668 M3PFNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLRTWM2OD1yLkS1OlY5KM7:TR?= M{DEO3NCVkeHUh?=
SF539 Mn3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTBwNEi2PFQh|ryP NW[4bZBlW0GQR1XS
LB2518-MEL MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofiTWM2OD1yLkS5O|A{KM7:TR?= M4fSPHNCVkeHUh?=
TE-441-T NIDTSYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU[5NGQ{UUN3ME2wMlUxOTJizszN M4qyRnNCVkeHUh?=
MDA-MB-134-VI MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{THPGlEPTB;MD61NFkzOSEQvF2= NVrLU2ExW0GQR1XS
SCC-3 NVfTbYxET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTqUZVKSzVyPUCuOVE5PzNizszN MnXYV2FPT0WU
KLE MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnW5TWM2OD1yLkWyNVcyKM7:TR?= MXrTRW5ITVJ?
LB2241-RCC M{izdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTBwNUK1NlUh|ryP NX\zRopuW0GQR1XS
NCI-H1417 MmrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37yS2lEPTB;MD61N|Q{PSEQvF2= M1TGOnNCVkeHUh?=
NCI-H2081 NVLlWpNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo[1TWM2OD1yLkW4OlEyKM7:TR?= MYHTRW5ITVJ?
NCI-H1522 MoHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXqUmR7UUN3ME2wMlU6Ozh|IN88US=> M4jnVHNCVkeHUh?=
NCI-H889 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37EdWlEPTB;MD61PVg1PCEQvF2= MYHTRW5ITVJ?
CGTH-W-1 NHHi[Y9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlyyTWM2OD1yLk[wO|U2KM7:TR?= MnewV2FPT0WU
EB-3 NUe3OoQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwNkGxOVMh|ryP Ml;0V2FPT0WU
D-336MG NGLWb3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTBwNkG3PVEh|ryP M3zCPHNCVkeHUh?=
LC-1F M{\JcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPUOINKSzVyPUCuOlI2QTJizszN M1\pRnNCVkeHUh?=
MHH-NB-11 Mle0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3YTWM2OD1yLk[zPFAyKM7:TR?= MY\TRW5ITVJ?
SK-N-FI M1LicGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHHTWM2OD1yLk[zPVEh|ryP M3\ZZ3NCVkeHUh?=
NCI-H69 NUfYfYRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGi1TWhKSzVyPUCuOlQ5PzlizszN NYn0UZpTW0GQR1XS
SCH NYn1O4xvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIi5TWdKSzVyPUCuOlYxOjNizszN M4fkVnNCVkeHUh?=
LS-513 NHe2OGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnyTWM2OD1yLk[3NlU6KM7:TR?= NGT5UGtUSU6JRWK=
CP67-MEL MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DMcmlEPTB;MD62O|U6PiEQvF2= NXLCXY1LW0GQR1XS
GCIY MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwN{CzOlMh|ryP MXLTRW5ITVJ?
SHP-77 NYXiTGtzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTBwN{C3N|Qh|ryP MnzyV2FPT0WU
EHEB NX7oUVdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXjTWM2OD1yLkexPFU1KM7:TR?= NYL4XWlYW0GQR1XS
D-247MG NG\6UJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\DTWM2OD1yLkezNlMzKM7:TR?= MoXvV2FPT0WU
Raji M3fPW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nPemlEPTB;MD63OFk5QSEQvF2= NFvFPIhUSU6JRWK=
MPP-89 NFvoVZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlKzTWM2OD1yLke1PVc5KM7:TR?= M3:1bHNCVkeHUh?=
EKVX Mk\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGm4c|ZKSzVyPUCuO|kxPzNizszN M4LOWnNCVkeHUh?=
HCC2218 NV76TGR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1P1RmlEPTB;MD63PVE{OSEQvF2= NU\IS4ZEW0GQR1XS
KNS-81-FD MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHn1emFKSzVyPUCuPFExOTFizszN MnLvV2FPT0WU
HCC2157 NWLFepRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3z0eWlEPTB;MD64OFk2OSEQvF2= NH[yT3JUSU6JRWK=
BT-474 Ml64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4T3d2lEPTB;MD64PFg2PCEQvF2= NFPMfFdUSU6JRWK=
NCI-H748 NGm2XXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1e0TmlEPTB;MD65NVIh|ryP NInUfFVUSU6JRWK=
EW-24 M13HV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrOTWM2OD1yLkmyNFAzKM7:TR?= NYXMdmxtW0GQR1XS
D-263MG M3vXd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vYTGlEPTB;MD65OFUyOiEQvF2= M3PCUHNCVkeHUh?=
OMC-1 M{jzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTBwOU[zO|Mh|ryP MnXqV2FPT0WU
NCI-H2196 M4jXW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIGySnNKSzVyPUCuPVc4PzdizszN MorMV2FPT0WU
HAL-01 M4HIW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYO1W5h{UUN3ME2wMlk6QDd{IN88US=> M2q2SXNCVkeHUh?=
NCI-H2107 M4K3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXGOZUyUUN3ME2xMlAyQDV2IN88US=> NELZTWlUSU6JRWK=
LB996-RCC MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXi1bWxkUUN3ME2xMlA5ODVzIN88US=> NFzBb5VUSU6JRWK=
NCI-H1395 MlzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmX0TWM2OD1zLkGwOlch|ryP Mo\mV2FPT0WU
CHP-126 MknIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTFwMU[xPVkh|ryP MofrV2FPT0WU
NB69 M3npdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;IU2NmUUN3ME2xMlI3OTR6IN88US=> NWXKeIw4W0GQR1XS
CAS-1 M332bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPte4RKSzVyPUGuN|QzOzFizszN MXLTRW5ITVJ?
JVM-3 M3P2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTFwNEe4OVUh|ryP MkjRV2FPT0WU
DMS-153 NYfKdVQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn[yTWM2OD1zLkW3Olc1KM7:TR?= Mm[4V2FPT0WU
SK-MEL-2 M2Tremdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPkTWM2OD1zLkexO|g6KM7:TR?= M1:wfHNCVkeHUh?=
NCI-H1155 NF\3UnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTFwN{O2O|Yh|ryP MXnTRW5ITVJ?
NCI-H1092 NX;wNmd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoSwTWM2OD1zLke2NVgzKM7:TR?= MmHpV2FPT0WU
LU-165 M4TIOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTFwOE[0O|Yh|ryP NV[zZVdKW0GQR1XS
HL-60 M3nOPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DtO2lEPTB;MT65PVkxQCEQvF2= NEO1bo9USU6JRWK=
REH NWn2VJZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4C2WmlEPTB;Mj6wNFU5OiEQvF2= M3LkR3NCVkeHUh?=
JVM-2 NGDjbpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLYTWM2OD1{LkC2NVM2KM7:TR?= MVnTRW5ITVJ?
MN-60 NWjSTmZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\RN2o{UUN3ME2yMlE4OzB6IN88US=> NGXzSY5USU6JRWK=
SCC-15 NIPTZ4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\XR5JKSzVyPUKuNlAzPyEQvF2= MnPhV2FPT0WU
SNU-C1 M1HPNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PicWlEPTB;Mj6yNVM1OyEQvF2= M{fTe3NCVkeHUh?=
SK-MEL-1 MnL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmC1TWM2OD1{LkOyNFQ4KM7:TR?= Mnf5V2FPT0WU
TGW M3fXd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37tSmlEPTB;Mj6zOVAzPyEQvF2= Mkn1V2FPT0WU
CA46 M4DJUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXwTHNDUUN3ME2yMlc2QTZ5IN88US=> MVzTRW5ITVJ?
NCI-H23 NHH4OIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrsVJBKSzVyPUKuPFA4QTFizszN MXnTRW5ITVJ?
MMAC-SF Mkf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTJwOE[2Nlgh|ryP NYqzU2lPW0GQR1XS
NCI-H2171 NVLtbI5mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mne4TWM2OD1|LkCzOFQ5KM7:TR?= MoHzV2FPT0WU
A704 NXTI[IpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTNwMUSxPVQh|ryP MV;TRW5ITVJ?
DB MoHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWL4OGl5UUN3ME2zMlI2PTd4IN88US=> M1vQOnNCVkeHUh?=
NCI-H719 NIPYRlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TjcmlEPTB;Mz6zNFM5PCEQvF2= MljJV2FPT0WU
MC-CAR NWXKSXhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTNwNUS4NVch|ryP NY\6dllzW0GQR1XS
SIMA MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDLTWM2OD1|LkW4OFE3KM7:TR?= MoDzV2FPT0WU
SW872 M2Dwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4e4dWlEPTB;Mz63PFExOSEQvF2= M1jRZ3NCVkeHUh?=
HCC1187 M3jENGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrlT4NTUUN3ME2zMlc5OzF3IN88US=> NYWySlFoW0GQR1XS
EW-13 M2HBSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PSWWlEPTB;Mz64N|QyPyEQvF2= MVzTRW5ITVJ?
NCI-SNU-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGiz[FBKSzVyPUSuNlE6QTlizszN MlHIV2FPT0WU
NCI-H226 NFX2WmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfVSWxKSzVyPUSuN|M3ODZizszN NYCzVIlOW0GQR1XS
RPMI-8866 M3vhSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX2zSWFSUUN3ME20MlM3ODJ7IN88US=> M4HI[3NCVkeHUh?=
OCI-AML2 MoqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrzTWM2OD12LkW1NlMh|ryP NF7MVnhUSU6JRWK=
LU-65 NF71fnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVL3PZRPUUN3ME20Mlk{ODN|IN88US=> Mn\qV2FPT0WU
SK-N-DZ MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fQWGlEPTB;NT62N|Q3PSEQvF2= M1LZbHNCVkeHUh?=
NB14 NWnJdFlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDne5RKSzVyPUWuPVcyOzVizszN MXHTRW5ITVJ?
COLO-829 MnvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnv5TWM2OD14LkOzN|U6KM7:TR?= M2qweXNCVkeHUh?=
MHH-CALL-2 NEniR3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHGNFhkUUN3ME22MlUyPTB6IN88US=> MkjpV2FPT0WU
NCI-H1770 NVPMe2pVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUSxNVVlUUN3ME22MlY3QTB2IN88US=> NGryZoZUSU6JRWK=
ECC4 M1TE[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\HdphKSzVyPU[uPFIyPzlizszN MmjLV2FPT0WU
A498 NUDZdJprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\1TWM2OD14Lki3NVkzKM7:TR?= MmXoV2FPT0WU
DMS-79 MnrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHYVGVKSzVyPUeuNFQ2OTJizszN MYXTRW5ITVJ?
P30-OHK NEXJSZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTdwMkG5NFYh|ryP NXK2W|hyW0GQR1XS
D-502MG MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnrS5NzUUN3ME23Mlk5OzZizszN NHLhVXNUSU6JRWK=
RCC10RGB NXv5fZM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTkTWM2OD16LkC2Nlgh|ryP M4n6OnNCVkeHUh?=
U-698-M MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;rPWlEPTB;OD6yPVIzPiEQvF2= MV;TRW5ITVJ?
BB49-HNC MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnm1TWM2OD17LkSyNlY2KM7:TR?= M1G4WXNCVkeHUh?=
ES1 MlHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGi4WI5KSzVyPUmuOlg6PTZizszN Mor6V2FPT0WU
MFM-223 MnrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\GVnlpUUN3ME2xNE46QTJ5IN88US=> NYHt[5ZHW0GQR1XS
C2BBe1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHKyfHBKSzVyPUGxMlM2OjNizszN MX7TRW5ITVJ?
EB2 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTF{Lk[4PFEh|ryP M1vLdXNCVkeHUh?=
C8166 MkTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DV[mlEPTB;MUOuPFMxOyEQvF2= NXm2cZJVW0GQR1XS
ES3 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojXTWM2OD1zMz65PVc4KM7:TR?= NGHubXpUSU6JRWK=
NCI-H1650 NXPBZmo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTyVXd{UUN3ME2xOk4{PzZ3IN88US=> MlvRV2FPT0WU
Mo-T NIThRpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTF5LkSwNlkh|ryP NXrMRVNmW0GQR1XS
NB7 MkXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;RTWM2OD1zNz63OFY4KM7:TR?= NH\SUHJUSU6JRWK=
ES7 NVXsUoQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTF7LkW1NFch|ryP M2C1b3NCVkeHUh?=
ES5 NVfWU3FnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\ZTWM2OD1{MT63OlcyKM7:TR?= NFvRbmhUSU6JRWK=
MSTO-211H MnSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlriTWM2OD1{MT64PFU5KM7:TR?= M33GZ3NCVkeHUh?=
U-87-MG MmrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTRWG1qUUN3ME2yOU4yQTZ4IN88US=> M{HDeXNCVkeHUh?=
THP-1 M{\mZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPWTWM2OD1{OT63NlAyKM7:TR?= NUjkfXJLW0GQR1XS
NB10 MmjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TrRWlEPTB;M{CuNlY6PCEQvF2= M3;aXXNCVkeHUh?=
NH-12 NVvSOIVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLlTWM2OD1|Mz6yNFE4KM7:TR?= NUDLOIxUW0GQR1XS
COLO-824 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfPTWM2OD1|ND6xNFA3KM7:TR?= MYrTRW5ITVJ?
SKM-1 M{HIfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvUTWM2OD1|Nz64OFIzKM7:TR?= MYXTRW5ITVJ?
NCI-H1838 Mnf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PvVWlEPTB;M{iuN|c6PyEQvF2= MmLOV2FPT0WU
RL NVjRe3hpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmC2TWM2OD1|OT6yOFc4KM7:TR?= NWjNN2hFW0GQR1XS
COLO-800 M2i3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfUTWM2OD12MD6wO|c{KM7:TR?= NVnQN497W0GQR1XS
KG-1 NYH1U2w5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHflWXVKSzVyPUSwMlg6PTVizszN MVLTRW5ITVJ?
TUR MmL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHwUnhKSzVyPUSxMlY{QTlizszN NI\SenpUSU6JRWK=
LNCaP-Clone-FGC MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Hpd2lEPTB;NEGuPVAyPyEQvF2= Mny0V2FPT0WU
NCI-H322M NEjCeFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTR{LkW5PFQh|ryP NI\hZYpUSU6JRWK=
LNCaP  NIjpfXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUS1ToVuUUN3ME25NU4{KG6P NGXXSmMzPTVyNUG3OC=>
C4-2 M2rXdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonKTWM2OD16IH7N M1v1eVI2PTB3MUe0
JURKAT MlTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV6yOEBp NHztOGpKSzVyPUSxOk43PiCwTR?= MVmyOFUyQTl7NR?=
MOLT-4 NWjGc|lZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DOUFI1KGh? MoXyTWM2OD1{OEWzMlUhdk1? MVOyOFUyQTl7NR?=
REH NF7mXohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnvdXN2OjRiaB?= MX;JR|UxRTJ6Nz62PEBvVQ>? M{W3blI1PTF7OUm1
NALM-6 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXMNlQhcA>? M3rSZWlEPTB;M{SzN|Ahdk1? MUOyOFUyQTl7NR?=
RS 4;11 NULYSIFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnrRnA4OjRiaB?= Mki4TWM2OD13MUmuNFUhdk1? NW\q[W1KOjR3MUm5PVU>
697 NV7T[WZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXQenJTOjRiaB?= MoW0TWM2OD1{MUC3MlEhdk1? M4nBblI1PTF7OUm1
SIL-ALL MnnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmP2NlQhcA>? M{PzPGlEPTB;MUm5Mlc4KG6P MVeyOFUyQTl7NR?=
CEM NILlVJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInsPIUzPCCq NUPwRlFjUUN3ME21Nk4yQCCwTR?= Mn;WNlQ2OTl7OUW=
P12 NWHsfVd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX21WWR5OjRiaB?= MnHOTWM2OD1|OT6yO{BvVQ>? NUjselZEOjR3MUm5PVU>
NALM-16 NIrMTW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkWwNlQhcA>? NHXEVppKSzVyPUm2MlI5KG6P M2XISVI1PTF7OUm1
JURKAT MlTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HEZ|Q5KGh? Mk\sTWM2OD1zND64OEBvVQ>? NXPGNJhxOjR3MUm5PVU>
MOLT-4 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PUc|Q5KGh? NFThboFKSzVyPUK2MlYhdk1? MV6yOFUyQTl7NR?=
REH MmrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPrWFU1QCCq NF;RSFdKSzVyPUS0MlcyKG6P M1\RfVI1PTF7OUm1
NALM-6 MnHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfhcnc1QCCq MmS5TWM2OD1{Mz6yOkBvVQ>? M4i1ZlI1PTF7OUm1
RS 4;11 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M16xRlQ5KGh? NV[2UFFCUUN3ME2xOlQvOjhibl2= NGnSZmQzPDVzOUm5OS=>
697 M1v0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXS0PEBp MoLyTWM2OD1|MEWuN{BvVQ>? MUOyOFUyQTl7NR?=
SIL-ALL MlTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXu0PEBp Mlu3TWM2OD15ND62NkBvVQ>? MVGyOFUyQTl7NR?=
CEM MmixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zBR|Q5KGh? NYm2[IdMUUN3ME2yOE42PSCwTR?= MVSyOFUyQTl7NR?=
P12 NYXYNVNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vFWFQ5KGh? M1TIfWlEPTB;MUiuOFYhdk1? MWeyOFUyQTl7NR?=
NALM-16 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVi0PEBp MofVTWM2OD14Mz6yOEBvVQ>? MkOwNlQ2OTl7OUW=
JURKAT MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLOW2g4OiCq NIrzdo1KSzVyPUOuOlUhdk1? Mmf3NlQ2OTl7OUW=
MOLT-4 MmnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXK3NkBp NIW1eFBKSzVyPUeuN|khdk1? M1HrdlI1PTF7OUm1
REH NXewco9yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TvclczKGh? MWLJR|UxRTF4LkCxJI5O M4[0blI1PTF7OUm1
NALM-6 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXe5eoJ{PzJiaB?= NVvuW5o3UUN3ME2xMlc5KG6P M3XTT|I1PTF7OUm1
RS 4;11 NEHCbHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2f5NFczKGh? MlL3TWM2OD12LkO4JI5O MWiyOFUyQTl7NR?=
697 NHPzTpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXm3NkBp MYLJR|UxRTd2LkK4JI5O NELXVVczPDVzOUm5OS=>
SIL-ALL MkOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnYNpVNPzJiaB?= NHz5UGFKSzVyPUeuNkBvVQ>? NG\ZXpAzPDVzOUm5OS=>
CEM M3fVPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml32O|IhcA>? MoHSTWM2OD13LkSyJI5O NXTDVHNzOjR3MUm5PVU>
P12 M17ib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{j6OFczKGh? NGS2V4lKSzVyPU[uN|chdk1? M1vUfFI1PTF7OUm1
NALM-16 NX74RZFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fXc|czKGh? MWTJR|UxRTd5LkezJI5O M{\qTVI1PTF7OUm1
Y79 NH\iZnBCeG:ydH;zbZMhSXO|YYm= Mny0NU02OCCwTR?= M370TlEzNzJ2IHi= MXXEUXNQ NHv5NY9qdmS3Y3XkJIFxd3C2b4Ppd{B4cGmlaDDjZY4h[mViZX7oZY5k\WRiYomgTHQ> NFO0ZVUzPDN4Nk[2OS=>
WER-Rb-1 NWXZfnk{SXCxcITvd4l{KEG|c3H5 NHLXUG0yNTVyIH7N MYSxNk8zPCCq NHjn[VJFVVOR M1;OO4lv\HWlZXSgZZBweHSxc3nzJJdpcWOqIHPhckBj\SCnbnjhcoNm\CCkeTDIWC=> MVKyOFM3PjZ4NR?=
G7 NFviVFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDoOJVqUUN3ME2zMlMhdk1? NUfaNoZxOjR{MES3N|M>
G166 NV7hbVdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXRTWM2OD15LkCgcm0> Mli0NlQzODR5M{O=
CB660 M{[5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LOR2lEPTB;Nj60JI5O Mkf1NlQzODR5M{O=
CB1117 NH2zS|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTzeZprUUN3ME2xOU43KG6P NWT4R5dNOjR{MES3N|M>
KB-3-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTFwNEigxtEhOC53MzDuUS=> NUT4PYxrOjN7NkK0OFU>
KB-8-5-11 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4i5dmlEPTB;NT6wNUDDuSB{LkCxJI5O M2Hl[VI{QTZ{NES1
KB-C-1 NET3VJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTF4Lke2JOKyKDRwNUGgcm0> MmPWNlM6PjJ2NEW=
KB-V-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmr0TWM2OD1{OEGuNlQhyrFiM{GuOVchdk1? NFTBZ2EzOzl4MkS0OS=>
OVCAR-8 NHv6enZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTdwMUmgxtEhOy54MDDuUS=> MorRNlM6PjJ2NEW=
NCI-ADR-RES MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTF{N{OuN|AhyrFiMUmxMlIxKG6P NEX3R4IzOzl4MkS0OS=>
MCF7 NFnS[IhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4qwVGlEPTB;NT6xNUDDuSBzLkS3JI5O NVfDdJVnOjN7NkK0OFU>
MCF7-FLV1000 NEPyVpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHP5b3lKSzVyPUO5N{4yQCEEsTC3OE45OyCwTR?= MlPHNlM6PjJ2NEW=
S1 NWn1e2hvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTycGZIUUN3ME2yOE4{OCEEsTC0Mlc2KG6P NX7WR4hMOjN7NkK0OFU>
S1-M1-80 M{GydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFWyOo1KSzVyPUK2NU4xPiEEsTC0PE4zPSCwTR?= M3PZSFI{QTZ{NES1
CORL-23/P NFfjW3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2m3Z2lEPTB;ND6zPEDDuSBzLkK1JI5O NInxXXIzOzl4MkS0OS=>
CORL-23/R MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TxZWlEPTB;NT6xOkDDuSBzLkizJI5O NE[3VpIzOzl4MkS0OS=>
NIH3T3 NIDPRm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmW2TWM2OD12MD62NEDDuSB2Lkm3JI5O MkXONlM6PjJ2NEW=
NIH3T3-G185 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHGTWM2OD1{NEGzMlQxKMLzIESyN{43PiCwTR?= NUPCU5J3OjN7NkK0OFU>
pcDNA-HEK293 NXLQNXFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXtc5BKSzVyPUKuO|UhyrFiMD62O{BvVQ>? MmDFNlM6PjJ2NEW=
MDR19-HEK293 NXvzNYt[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3q3UWlEPTB;OEWuOVAhyrFiMUOuOlchdk1? NEP4OJczOzl4MkS0OS=>
R482-HEK293 NHLUU|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml:xTWM2OD1{NT65O{DDuSB2Lkm1JI5O NIXHT4szOzl4MkS0OS=>
MRP1-HEK293 M1rJ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mof2TWM2OD1{Lkm5JOKyKDFwNEmgcm0> MUmyN|k3OjR2NR?=
SF188 NH;iUoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fRZ|ExNTFyMDDuUS=> NU\pTYdWOjRvOU[gbC=> MYLEUXNQ NH3tdG9qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CClb37j[Y51emG2aX;uMUBl\XCnZHXueEBu[W6wZYK= M3u0XFI{QDh5NkS1
T98G NHr1VHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUT5RWdZOTBvMUCwJI5O M1H1WFI1NTl4IHi= Mn7WSG1UVw>? MYHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiClb37j[Y51emG2aX;uMUBl\XCnZHXueEBu[W6wZYK= M2nDclI{QDh5NkS1
DU145 NXz3RVUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjUXnczTE2VTx?= NGLTTI1KSzVy4pk8OlAhdk1? M{DxSFI{QDh2NEK4
LNCaP  NUXGO2lUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfEUXNQ MljvTWM2OOLKvEe1JI5O M2DW[|I{QDh2NEK4
PC3 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFr1TI5FVVOR M33z[2lEPTEkiMyxO|Uhdk1? M2iydFI{QDh2NEK4
RT4 NYLWWItPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\ITWM2OD1{Nz6yNUBvVQ>? NWW5bWJLOjN5OUK2N|k>
5637 Mlj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEL3cYtKSzVyPUS1MlQ4KG6P NF62bVQzOzd7Mk[zPS=>
T24 NEXMXolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFn3epNKSzVyPUe5MlEzKG6P MYGyN|c6OjZ|OR?=
MCF7  NX:1W|FSTnWwY4Tpc44hSXO|YYm= MXWxNFAhdk1? MkLMNUBp MV\EUXNQ M{DEd5Jm\HWlZYOgeIhmKGmwZIXjeIlwdiCxZtMgS5Jm[jFuwrDT[4syNMLiUIOyMOKhW2W{cHnuZVMtKGGwZNMgW4l{eDJ? MmnlNlM4PzB{NES=
KB-V1  NXXUW|lGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofITWM2OD1|LkmyJO69VQ>? M4TuS|I{PTl|MUm2
Hec50co NVz1dmY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDT[HVGUUN3ME21JI5O Mk[2NlMyPDZ4OEe=
MDA-MB-468 NGL3N41CeG:ydH;zbZMhSXO|YYm= NITqcHgyNzVxMUCgcm0> NGX5XWEzPC92OD:3NkBp NVPoR5o6TE2VTx?= M3y0OIlv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MmPGNlMyPDR{OUS=
MCF10A M{fESWFxd3C2b4Ppd{BCe3OjeR?= NHfpW|IyNzVxMUCgcm0> NUThbIZQOjRxNEivO|IhcA>? NIXIelVFVVOR M4DwTYlv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NYLzenNwOjNzNESyPVQ>
Huh-7 M3jkS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLKdY1WOS9zMD:xNFAwOTByMDDuUS=> MlLSOFghcA>? MYTk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JIRwe2VvZHXw[Y5l\W62bIm= Ml:0NlI4PDV3OEe=
Daoy  MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mni4NU45PzVvMkSwJI5O NXf2WoxtPzJiaB?= MljhSG1UVw>? NXK5T2JOUUN3ME21JI5O NYrQWZRGOjJ|OUCyO|k>
ONS-76 NVPHc5V4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXRXYNqOS56N{WtNlQxKG6P NYHMV5dQPzJiaB?= MoXMSG1UVw>? MmGxTWM2OD15LkWgcm0> Ml;TNlI{QTB{N{m=
SUM 149 M{S2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrYe|loOC1zMECgcm0> M2e4UFczKGh? MUnpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wYYK= M1HFV|IzOzB7OUO5
MDA-MB-231 NIDlO2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1naUVAuOTByIH7N MVe3NkBp Ml;nbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnHy M3XkU|IzOzB7OUO5
HR5 M4DrfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVSwMVExOCCwTR?= M3\0RlczKGh? MmLsbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnHy Mln6NlI{ODl7M{m=
BT-474-M1 NYnHOmluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fvW|AuOTByIH7N MV[3NkBp NYDjbnB4cW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoFz NHvkZpMzOjNyOUmzPS=>
AU565 M2TWW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXOwMVExOCCwTR?= M2\xSFczKGh? Mn7WbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnHy NHXTT4EzOjNyOUmzPS=>
T47D MnfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUOwMVExOCCwTR?= NVzIeHJ5PzJiaB?= MliybY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnHy NVi2bIFoOjJ|MEm5N|k>
MCF7 NX\1d2JQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETnW2IxNTFyMDDuUS=> NW\te4Y{PzJiaB?= NVm3RmNqcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoFz NEHKRlIzOjNyOUmzPS=>
HCT116p53(+/+) MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{P4cVExNTFyMECgcm0> MlzCNlQwPDhiaB?= NYXUcGtrcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGOxbYDs[ZRmdHliYYSgNlUhdk1? M4rUOVIzOjZ{MUex
HCT116p53(-/-) MlXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jQWFExNTFyMECgcm0> NX:yfJBXOjRxNEigbC=> NWn2SGlXcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGOxbYDs[ZRmdHliYYSgNlUhdk1? M{fmVlIzOjZ{MUex
HeLa  MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2ezUlExNTFyMDDuUS=> M4jmRVQ5KGh? M4HRWmROW09? MmXwTWM2OD13Mj65JI5O NHnJdIgzOjB6MEKzOS=>
HeLa  Mm[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvyfXEyOC1zMECgcm0> M1\ke|czKGh? NHv4[IRFVVOR M1\o[2lEPTB;NUCuOUBvVQ>? MX:yNlA5ODJ|NR?=
GBC NYC1WXdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPnSGQ4OiCq M17WUmlEPTB;MUSuO|ghdk1? MWGyNVk3PTd|OR?=
GB-CL-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWS3NkBp MUnJR|UxRTVwMkKgcm0> M{\KRVIyQTZ3N{O5
Mz-ChA-2 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGX4eJM4OiCq MniyTWM2OD1|LkOxJI5O NXqzNJpVOjF7NkW3N|k>
TGBC1-TKB NInCR|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHCNVQ1KGh? MYnJR|UxRTZwN{Kgcm0> NWHBTFBGOjF7NkW3N|k>
Wittier NYjqdnFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2THd|czKGh? MXLJR|UxRTNwMk[gcm0> MnrqNlE6PjV5M{m=
H-1 Mlj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYi3NkBp NG\wdmZKSzVyPUmuOVQhdk1? M4PxVVIyQTZ3N{O5
HuH-28 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjtO|IhcA>? MmnBTWM2OD1zMT6xPUBvVQ>? NIjxRlEzOTl4NUezPS=>
NEC MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vqWFczKGh? Mm\ITWM2OD17Lkm4JI5O NHjtNGwzOTl4NUezPS=>
REB MnnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVK3NkBp MXLJR|UxRTF|LkWxJI5O NIjVVVkzOTl4NUezPS=>
CC-LP-1 MnH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITMeFY4OiCq MlH6TWM2OD13Lki0JI5O NXK0PFdSOjF7NkW3N|k>
CC-SW-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\wW3c4OiCq MnS3TWM2OD17LkW1JI5O NGq0bGozOTl4NUezPS=>
EGI-1 M3LRW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV23NkBp NXnFb4l{UUN3ME2xNE44OiCwTR?= NF\6T5kzOTl4NUezPS=>
Sk-ChA-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fweFczKGh? MmXHTWM2OD1zNz6yJI5O NFPocVIzOTl4NUezPS=>
TFK-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTRO|IhcA>? NIfHfY1KSzVyPUGzMlQ2KG6P NGTjZnMzOTl4NUezPS=>
786-O NGHBW3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLpb|VzPS16MDDuUS=> NWf0VYF6QTZiaB?= NUnsWVNYUEOu NW\kXXpLe3WycILld5NmeyC2aHWgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meiC5aYToJGlEPTEEoI\hcJVmeyCxZjCyJJRwKDJyIH7N MoTBNlE3PDJ|N{S=
A498 MlPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\INlUuQDBibl2= M1K0eVk3KGh? MmXLTGNt NFPtUYt{fXCycnXzd4V{KHSqZTDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKHerdHigTWM2OMLidnHseYV{KG:oIEKgeI8hOjBibl2= Mn;oNlE3PDJ|N{S=
ACHN MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYi1MVgxKG6P NEjJO5k6PiCq M2LYNmhEdA>? NXPKN5Fwe3WycILld5NmeyC2aHWgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meiC5aYToJGlEPTEEoI\hcJVmeyCxZjCyJJRwKDJyIH7N NE\DVJQzOTZ2MkO3OC=>
Caki-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrCV|J2PS16MDDuUS=> NXXzcJRUQTZiaB?= MlnZTGNt M{LzS5N2eHC{ZYPz[ZMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIhf2m2aDDJR|UxyqC4YXz1[ZMhd2ZiMjD0c{AzOCCwTR?= NYroOHZ3OjF4NEKzO|Q>
SN12C NUXwd|B3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2O2bFUuQDBibl2= MWO5OkBp Mn7RTGNt NV:xVWJ{e3WycILld5NmeyC2aHWgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meiC5aYToJGlEPTEEoI\hcJVmeyCxZjCyJJRwKDJyIH7N MXiyNVY1OjN5NB?=
HMC-1.1 MmHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\0UFEuOTByMDDuUS=> NVjHU5diPzJiaB?= NI\MRmpqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmV? M{LOeFIyOjR{MUi5
HMC-1.2 NFWwWFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWWxMVExODBibl2= MVK3NkBp NGPlbFhqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmV? NIrMVGQzOTJ2MkG4PS=>
C2 M33KN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFn0XHIyNTFyMECgcm0> M2TaPFczKGh? M1fxZ4lvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\Q>? NV7DWIpmOjF{NEKxPFk>
CHP-212 Mm\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDIcpgyNTF{NTDuUS=> MUmyOE0yOjBiaB?= NEeycZZqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7l NILqb2QzOTF4OUK0Ni=>
IMR-32 NXPlfoVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vSSlEuOTJ3IH7N NIfJfXIzPC1zMkCgbC=> MnrXbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZR?= NGXGUVQzOTF4OUK0Ni=>
Kelly NFf6WFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIi3c4IyNTF{NTDuUS=> NVK5WJY4OjRvMUKwJIg> M13DU4lvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnW= NHvLTHYzOTF4OUK0Ni=>
SH-EP MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHke5AyNTF{NTDuUS=> MV6yOE0yOjBiaB?= M3XMbYlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnW= MWmyNVE3QTJ2Mh?=
SH-SY5Y MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXOxMVEzPSCwTR?= NXnQO|NoOjRvMUKwJIg> NUTSe3ZkcW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[S=> NVfhUlR3OjFzNkmyOFI>
SK-N-AS NVL5[oh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\NV|EuOTJ3IH7N MnuyNlQuOTJyIHi= M3i0OolvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnW= MmWyNlEyPjl{NEK=
SK-N-BE NXH3WmF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TqdlEuOTJ3IH7N MorYNlQuOTJyIHi= MlPBbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZR?= MnLUNlEyPjl{NEK=
KG1 NXe5WVFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLUVlMyNzFyL{GwNEBvVQ>? M4Lzb|czKGh? NIfNWWhFVVOR NYK2VWROcW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[S=> NWLuSYoyOTl2NUizOVg>
U937 NWXuT5lJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LmclEwOTBxMUCwJI5O M4PjdlczKGh? MULEUXNQ NGfFd4RqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7l MYSxPVQ2QDN3OB?=
CAL62 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTUUnZkOC5zLUGwNEBvVQ>? MmnCO|IhcA>? MoX4SG1UVw>? MoTHSWM2OD1zLkSgcm0> NYGyW214OTl{MkO1OVM>
OCUT-1 Mn\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1Ts[lAvOS1zMECgcm0> MmL4O|IhcA>? M2Dlb2ROW09? M2jxZmVEPTB;Mj6zJI5O MV:xPVIzOzV3Mx?=
8505C NXHK[XdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIryV2sxNjFvMUCwJI5O NX3iVndNPzJiaB?= NEnxOJJFVVOR NUHJdGdwTUN3ME2zMlIhdk1? NXLXT21mOTl{MkO1OVM>
ACT-1 M2XYOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPQNE4yNTFyMDDuUS=> MVK3NkBp NFfldpZFVVOR MmHBSWM2OD13LkSgcm0> NEf6e2QyQTJ{M{W1Ny=>
SW1736 NVTYcGdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzyNE4yNTFyMDDuUS=> MVy3NkBp NYDHe3J1TE2VTx?= MmrSSWM2OD13Lk[gcm0> MoDoNVkzOjN3NUO=

... Click to View More Cell Line Experimental Data

In vivo BI 2536 given i.v. once or twice per week is highly efficacious in diverse xenograft models with acceptable tolerability by inhibiting cell proliferation through a mitotic arrest, and subsequently induction of tumor-cell death. Administration of BI 2536 at 50 mg/kg once or twice per week significantly inhibits growth of HCT 116 xenografts with T/C of 15% and 0.3%, respectively. BI 2536 treatment twice-weekly also leads to excellent tumor-growth in BxPC-3 and A549 models with T/C of 5% and 14%, respectively. [1]

Protocol

Kinase Assay:[1]
+ Expand

Plk1 in vitro kinase assay:

Recombinant human Plk1 (residues 1-603) is expressed as N-terminal, GST-tagged fusion protein with a baculoviral expression system and purified by affinity chromatography with Glutathione-agarose. Enzyme activity assays for Plk1 are performed in the presence of serially diluted BI 2536 with 20 ng of recombinant kinase and 10 μg casein from bovine milk as the substrate. Kinase reactions are performed in a final volume of 60 μL for 45 minutes at 30 °C (15 mM MgCl2, 25 mM MOPS [pH 7.0], 1 mM DTT, 1% DMSO, 7.5 mM ATP, 0.3 μCi γ-33P-ATP). Reactions are terminated by the addition of 125 μL of ice-cold 5% TCA. After transfer of the precipitates to Multi-Screen mixed ester cellulose filter plates, plates are washed with 1% TCA and quantified radiometrically. Dose-response curve is used for calculating IC50 value.
Cell Research:[1]
+ Expand
  • Cell lines: HeLa, A43, SKOV-3, HT-29, K562, A549, Saos-2, MCF7, HCT116, COLO 205, Hep G2, Raji and PC-3 cells, etc.
  • Concentrations: Dissolved in DMSO, final concentrations ~1 μM
  • Incubation Time: 24 and 72 hours
  • Method: Cells are exposed to various concentrations of BI 2536 for 24, and 72 hours. Cell growth is assessed by the measurement of Alamar Blue dye conversion in a fluorescence spectrophotometer. For determining the DNA content of the cultures, cell suspensions are fixed in 80% ethanol, treated for 5 minutes with 0.25% Triton X-100 in PBS, and incubated with 0.1% RNase and 10 μg/mL propidium iodide (PI) in PBS for 20 minutes at RT. Cell-cycle profiles are determined by flow cytometric analysis.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Female BomTac:NMRI-Foxn1nu mice injected subcutaneously with HCT 116, NCI-H460, or A549 cells
  • Formulation: Formulated in hydrochloric acid (0.1 N), and diluted with 0.9% NaCl
  • Dosages: ~50 mg/kg
  • Administration: Injection i.v. once or twice per week
    (Only for Reference)

Solubility (25°C)

In vitro Ethanol 100 mg/mL (191.69 mM)
DMSO 21 mg/mL (40.25 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG 400+0.5% Tween 80+5% Propylene glycol
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 521.66
Formula

C28H39N7O3

CAS No. 755038-02-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00526149 Completed Breast Cancer|Endometrial Cancer|Head and Neck Cancer|Melanoma (Skin)|Ovarian Cancer|Sarcoma European Organisation for Research and Treatment of Cancer - EORTC July 2007 Phase 2
NCT00526149 Completed Breast Cancer|Endometrial Cancer|Head and Neck Cancer|Melanoma (Skin)|Ovarian Cancer|Sarcoma European Organisation for Research and Treatment of Cancer - EORTC July 2007 Phase 2
NCT02215044 Terminated Pancreatic Neoplasms Boehringer Ingelheim June 2007 Phase 1
NCT02215044 Terminated Pancreatic Neoplasms Boehringer Ingelheim June 2007 Phase 1
NCT00412880 Completed Carcinoma Small Cell Boehringer Ingelheim January 2007 Phase 2
NCT00412880 Completed Carcinoma Small Cell Boehringer Ingelheim January 2007 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    We need to use BI 2536 in preclinical studies using mice, how to formulate the inhibitor for this in vivo study?

  • Answer:

    For in vivo study, DMSO should not be more than 5% because the toxicity. You can formulated BI2536 in hydrochloric acid (0.1 N), and diluted with 0.9% NaCl for animal study according to the reference :( Supplemental Data) http://linkinghub.elsevier.com/retrieve/pii/S0960-9822(06)02671-6

PLK Signaling Pathway Map

PLK Inhibitors with Unique Features

Related PLK Products4

Tags: buy BI 2536 | BI 2536 supplier | purchase BI 2536 | BI 2536 cost | BI 2536 manufacturer | order BI 2536 | BI 2536 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID